(Q81554401)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18591148%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

title

MAO-B inhibitors: multiple roles in the therapy of neurodegenerative disorders? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18591148%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

author name string

P Foley

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18591148%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

M Gerlach

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18591148%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

M B Youdim

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18591148%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

P Riederer

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18591148%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

publication date

1 January 2000

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18591148%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

number of pages

23

1 reference

Parkinsonism and Related Disorders

inferred from page(s)

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18591148%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

volume

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18591148%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18591148%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

page(s)

25-47

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18591148%20AND%20SRC:MED&resulttype=core&format=json

Some observations upon a new inhibitor of monoamine oxidase in brain tissue.

9 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Assignment of genes for human monoamine oxidases A and B to the X chromosome

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Human monoamine oxidase A and B genes exhibit identical exon-intron organization

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

The effect of lipophilic compounds upon the activity of rat liver mitochondrial monoamine oxidase-A and -B.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Selective acetylenic 'suicide' and reversible inhibitors of monoamine oxidase types A and B

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Determination of regions important for monoamine oxidase (MAO) A and B substrate and inhibitor selectivities

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Guinea pig striatum as a model of human dopamine deamination: the role of monoamine oxidase isozyme ratio, localization, and affinity for substrate in synaptic dopamine metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Distribution of the two forms of monoamine oxidase within monoaminergic neurons of the guinea pig brain.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Molecular neuroanatomy of human monoamine oxidases A and B revealed by quantitative enzyme radioautography and in situ hybridization histochemistry

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Turnover of brain monoamine oxidase measured in vivo by positron emission tomography using L-[11C]deprenyl.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Slow recovery of human brain MAO B after L-deprenyl (Selegeline) withdrawal

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Distinct monoamine oxidase A and B populations in primate brain.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Localization of distinct monoamine oxidase a and monoamine oxidase b cell populations in human brainstem

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Topographic immunocytochemical mapping of monoamine oxidase-A, monoamine oxidase-B and tyrosine hydroxylase in human post mortem brain stem

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Demonstration of monoamine oxidase-A and -B in the human brainstem by a histochemical technique

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Monoamine oxidases: from brain maps to physiology and transgenics to pathophysiology.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Platelet monoamine oxidase B: use and misuse

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Visualization of monoamine oxidase in human brain.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Monoamine oxidase, brain ageing and degenerative diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Ontogenesis of monoamine oxidase-A and -B in the human brain frontal cortex

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Differential age-related changes of MAO-A and MAO-B in mouse brain and peripheral organs

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Effect of aging on lazabemide binding, monoamine oxidase activity and monoamine metabolites in human frontal cortex

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Biphasic and region-specific MAO-B response to aging in normal human brain.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Increased monoamine oxidase B activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative enzyme radioautography

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Platelet MAO-B activity and the psychopathology of Parkinson's disease, senile dementia and multi-infarct dementia.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Inhibition of monoamine oxidase B in the brains of smokers

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Hypertensive interactions between monoamine oxidase inhibitors and foodstuffs

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Substrate regulation of monoamine oxidases

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

N-Methyl-N-2-propynyl-1-indanamine. A Potent Monoamine Oxidase Inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Tyramine antagonistic properties of AGN 1135, an irreversible inhibitor of monoamine oxidase type B.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

(E)-2-(3,4-dimethoxyphenyl)-3-fluoroallylamine: a selective, enzyme-activated inhibitor of type B monoamine oxidase

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

MDL 72,974: a potent and selective enzyme-activated irreversible inhibitor of monoamine oxidase type B with potential for use in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Measurement of human cerebral monoamine oxidase type B (MAO-B) activity with positron emission tomography (PET): a dose ranging study with the reversible inhibitor Ro 19-6327

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Selective and potent monoamine oxidase type B inhibitors: 2-substituted 5-aryltetrazole derivatives

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

The novel neuropsychotropic agent milacemide is a specific enzyme-activated inhibitor of brain monoamine oxidase B

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Milacemide increases 5-hydroxytryptamine and dopamine levels in rat brain--possible mechanisms of milacemide antimyoclonic property in the p,p'-DDT-induced myoclonus

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

The interactions of milacemide with monoamine oxidase

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Species differences in the interactions of the anticonvulsant milacemide and some analogues with monoamine oxidase-B

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Inactivation of monoamine oxidase B by analogues of the anticonvulsant agent milacemide (2-(n-pentylamino)acetamide)

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Clinical pharmacokinetics and pharmacodynamics of selegiline. An update

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

On the mode of action of L-deprenyl in the human central nervous system

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Mapping human brain monoamine oxidase A and B with 11C-labeled suicide inactivators and PET

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Amphetamine and 2-phenylethylamine in post-mortem Parkinsonian brain after (-)deprenyl administration

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Desmethylselegiline, a metabolite of selegiline, is an irreversible inhibitor of monoamine oxidase type B in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Modulation of gene expression rather than monoamine oxidase inhibition: (-)-deprenyl-related compounds in controlling neurodegeneration

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Integrated pharmacokinetic and metabolic modeling of selegiline and metabolites after transdermal administration

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Selegiline in de novo parkinsonian patients: the Finnish study

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Pharmacokinetics and pharmacodynamics of the monoamine oxidase B inhibitor mofegiline assessed during a phase I dose tolerance trial

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Antiepileptic drug pharmacokinetics and neuropharmacokinetics in individual rats by repetitive withdrawal of blood and cerebrospinal fluid: milacemide

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Evaluation of multiple doses of milacemide in the treatment of senile dementia of the Alzheimer's type

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Mixed linear and non-linear disposition of lazabemide, a reversible and selective inhibitor of monoamine oxidase B

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Pharmacodynamics of lazabemide, a reversible and selective inhibitor of monoamine oxidase B

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Pharmacokinetics and pharmacodynamics of single and multiple doses of the MAO-B inhibitor lazabemide in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

A controlled trial of lazabemide (Ro 19-6327) in levodopa-treated Parkinson's disease. Parkinson Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Effect of lazabemide on the progression of disability in early Parkinson's disease. The Parkinson Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Evidence for dopamine deamination by both type A and type B monoamine oxidase in rat brain in vivo and for the degree of inhibition of enzyme necessary for increased functional activity of dopamine and 5-hydroxytryptamine

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

A dose-ranging study of selegiline in patients with Parkinson's disease: effect of platelet monoamine oxidase activity

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Monoamine oxidase-dependent metabolism of dopamine in the striatum and substantia nigra of L-DOPA-treated monkeys.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Does the B form selective monoamine oxidase inhibitor lose selectivity by long term treatment?

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Deprenil: loss of selectivity for inhibition of B-type MAO after repeated treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Pharmacology of selegiline

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Tyramine pressor sensitivity changes during deprenyl treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

The contribution of amphetamine metabolites of (-)-deprenyl to its antiparkinsonian properties

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Absence of "cheese effect" during deprenyl therapy: some recent studies.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Relationship between tyramine potentiation and selective inhibition of monoamine oxidase types A and B in the rat vas deferens

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Selegiline diminishes cardiovascular autonomic responses in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Prevalence of orthostatic hypotension in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Selectivity of MDL 72,974A for MAO-B inhibition based on substrate and metabolite concentrations in plasma

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Effect of L-deprenyl, its structural analogues and some monoamine oxidase inhibitors on dopamine uptake

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Effects of the glycine prodrug milacemide (2-N-pentylaminoacetamide) on catecholamine secretion from isolated adrenal medulla chromaffin cells

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

The molecular pharmacology of L-deprenyl

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Chronic L-deprenyl-induced up-regulation of the dopamine uptake carrier

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

The effect of long-term treatment with deprenyl on basal and L-dopa evoked dopamine release in vitro from the corpus striatum of aged rats

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

(-)Deprenyl-Medication: A Strategy To Modulate the Age-Related Decline of the Striatal Dopaminergic System

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Reduced striatal tyrosine hydroxylase activity is not accompanied by change in responsiveness of dopaminergic receptors following chronic treatment with deprenyl.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Effects of selective monoamine oxidase inhibitors on the in vivo release and metabolism of dopamine in the rat striatum.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Effects of monoamine oxidase and catechol-O-methyltransferase inhibition on dopamine turnover: a PET study with 6-[18F]L-DOPA.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Striatal 6-[18F]fluorodopa accumulation after combined inhibition of peripheral catechol-O-methyltransferase and monoamine oxidase type B: differing response in relation to presynaptic dopaminergic dysfunction.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

In vivo mechanisms underlying dopamine release from rat nigrostriatal terminals: II. Studies using potassium and tyramine.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Influence of selective inhibition of monoamine oxidase A or B on striatal metabolism of L-DOPA in hemiparkinsonian rats

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Aliphatic N-methylpropargylamines: monoamine oxidase-B inhibitors and antiapoptotic drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

In vitro effects on monoamine uptake and release by the reversible monoamine oxidase-B inhibitors Lazabemide and N-(2-aminoethyl)-p-chlorobenzamide: A comparison with l-deprenyl

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Effect of milacemide on extracellular and tissue concentrations of dopamine and 5-hydroxytryptamine in rat frontal cortex

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Species differences in the deamination of dopamine and other substrates for monoamine oxidase in brain

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

A behavioural and neurochemical analysis of chronic and selective monoamine oxidase inhibition.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

(-)Deprenyl and (-)1-phenyl-2-propylaminopentane, [(-)PPAP], act primarily as potent stimulants of action potential-transmitter release coupling in the catecholaminergic neurons

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Novel (-)deprenyl-derived selective inhibitors of B-type monoamine oxidase. The relation of structure to their action

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

2-Phenylethylamine: a modulator of catecholamine transmission in the mammalian central nervous system?

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Phenylethylaminergic modulation of catecholaminergic neurotransmission

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Determination of 2-phenylethylamine in rat brain after MAO inhibitors, and in human CSF and urine by capillary GC and chemical ionization MS

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Monoamine oxidase-B inhibition: a comparison of in vivo and ex vivo measures of reversible effects

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

The effects of administration of monoamine oxidase-B inhibitors on rat striatal neurone responses to dopamine

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Phenylethylamine-induced stereotypies in the rat: a behavioral test system for assessment of MAO-B inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Behavioral sensitization to beta-phenylethylamine (PEA): enduring modifications of specific dopaminergic neuron systems in the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Deprenyl induces the tyrosine hydroxylase enzyme in the rat dopaminergic nigrostriatal system.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

(-)-Deprenyl a selective MAO "B' inhibitor, increases [3H]imipramine binding and decreases beta-adrenergic receptor function

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Effect of selective monoamine oxidase inhibition by clorgyline and deprenyl on the norepinephrine receptor-coupled adenylate cyclase system in rat cortex

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Behavioral and neurochemical effects induced by subchronic l-deprenyl administration.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

The effects of lifelong treatment with MAO inhibitors on amino acid levels in rat brain

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Milacemide effects on the temporal inter-relationship of amino acids and monoamine metabolites in rat cerebrospinal fluid

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Deprenyl suppresses the oxidant stress associated with increased dopamine turnover

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Protection of the aged substantia nigra of the rat against oxidative damage by (-)-deprenyl

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

The striatal dopamine dependency of life span in male rats. Longevity study with (-)deprenyl

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

(-) deprenyl induces activities of both superoxide dismutase and catalase but not of glutathione peroxidase in the striatum of young male rats

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

(?)-Deprenyl can induce soluble superoxide dismutase in rat striata

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

The effect of L-deprenyl, D-deprenyl and MDL72974 on mitochondrial respiration: a possible mechanism leading to an adaptive increase in superoxide dismutase activity

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

The effect of pergolide and MDL 72974 on rat brain CuZn superoxide dismutase

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Selegiline and lymphocyte superoxide dismutase activities in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Deprenyl effects on levodopa pharmacodynamics, mood, and free radical scavenging

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Hydroxyl and peroxyl radical trapping by the monoamine oxidase-B inhibitors deprenyl and MDL 72,974A: implications for protection of biological substrates

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Effects of alpha-phenyl-tert-butylnitrone and selegiline on hydroxyl free radicals in rat striatum produced by local application of glutamate.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

MPTP-induced deficits in motor activity: neuroprotective effects of the spintrapping agent, alpha-phenyl-tert-butyl-nitrone (PBN)

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

In vivo hydroxylation of the neurotoxin, 1-methyl-4-phenylpyridinium, and the effect of monoamine oxidase inhibitors: electrospray-MS analysis of intra-striatal microdialysates.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

MAO inhibitors, clorgyline and lazabemide, prevent hydroxyl radical generation caused by brain ischemia/reperfusion in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

The interaction of monoamine oxidases with tertiary amines

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Neuronal protective and rescue effects of deprenyl against MPP+ dopaminergic toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Suppression of hydroxyl radical formation and protection of nigral neurons by l-deprenyl (selegiline)

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

(-)-Deprenyl protection of 1-methyl-4 phenylpyridium ion (MPP+)-induced apoptosis independent of MAO-B inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

L-deprenyl fails to protect mesencephalic dopamine neurons and PC12 cells from the neurotoxic effect of 1-methyl-4-phenylpyridinium ion.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Inhibition of MAO B, but not MAO A, blocks DSP-4 toxicity on central NE neurons.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Protection against DSP-4-induced neurotoxicity by deprenyl is not related to its inhibition of MAO B.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Neuroprotective effects of some monoamine oxidase-B inhibitors against DSP-4-induced noradrenaline depletion in the mouse hippocampus

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Immunohistochemical evidence of neuroprotection by R(-)-deprenyl and N-(2-hexyl)-N-methylpropargylamine on DSP-4-induced degeneration of rat brain noradrenergic axons and terminals.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Pharmacological modifications of the neurotoxic action of the noradrenaline neurotoxin DSP4 on central noradrenaline neurons

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

L-deprenyl protects mesencephalic dopamine neurons from glutamate receptor-mediated toxicity in vitro.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Inhibition of MAO-B protects against MDMA-induced neurotoxicity in the striatum

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

L-(-)-desmethylselegiline, a metabolite of selegiline [L-(-)-deprenyl], protects mesencephalic dopamine neurons from excitotoxicity in vitro.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

R(-)-deprenyl potentiates dopamine-induced cytotoxicity toward catecholaminergic neuroblastoma SH-SY5Y cells

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Rescue of dying neurons: A new action for deprenyl in MPTP parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Deprenyl reduces the death of motoneurons caused by axotomy

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

(-)-Deprenyl attenuates spinal motor neuron degeneration and associated locomotor deficits in rats subjected to spinal cord ischemia.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

(-)-Deprenyl increases the survival of rat retinal ganglion cells after optic nerve crush

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Attenuation of 1-methyl-4-phenylpyridinium (MPP+) neurotoxicity by deprenyl in organotypic canine substantia nigra cultures.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

(-)-Deprenyl reduces PC12 cell apoptosis by inducing new protein synthesis

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Mitochondrial membrane potential and nuclear changes in apoptosis caused by serum and nerve growth factor withdrawal: time course and modification by (-)-deprenyl.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

R-deprenyl and R-2-heptyl-N-methylpropargylamine prevent apoptosis in cerebellar granule neurons induced by cytosine arabinoside but not low extracellular potassium.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Increased CNTF gene expression in process-bearing astrocytes following injury is augmented by R(-)-deprenyl.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Glyceraldehyde-3-phosphate dehydrogenase, the putative target of the antiapoptotic compounds CGP 3466 and R-(-)-deprenyl

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

L-Deprenyl and MDL72974 do not improve the recovery of dopaminergic cells following systemic administration of MPTP in mouse.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Sparing by rasagiline (TVP-1012) of cholinergic functions and behavior in the postnatal anoxia rat.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Increased survival of dopaminergic neurons by rasagiline, a monoamine oxidase B inhibitor.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Titration of human brain monoamine oxidase -A and -B by clorgyline and L-deprenil

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

The concept of astrocyte-kinetic drug in the treatment of neurodegenerative diseases: evidence for L-deprenyl-induced activation of reactive astrocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Selegiline as immunostimulant--a novel mechanism of action?

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Selegiline enhances NGF synthesis and protects central nervous system neurons from excitotoxic and ischemic damage.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Modulation of the NMDA receptor by polyamines

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

The relevance of glial monoamine oxidase-B and polyamines to the action of selegiline in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

The anticonvulsant effect of deprenyl on pentylenetetrazol-induced seizures in Lewis rats

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Antitumor effect of L-deprenyl in rats with carcinogen-induced mammary tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Inhibition of bovine brain calmodulin-dependent cyclic nucleotide phosphodiesterase isozymes by deprenyl

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Pharmacological actions of l-deprenyl (selegiline) and other selective monoamine oxidase B inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Levodopa: is toxicity a myth?

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

The potentiation of the anti akinetic effect after L-Dopa treatment by an inhibitor of Mao-B, deprenil

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Role of selegiline in combination therapy of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Symptomatic effect of selegiline in de novo Parkinsonian patients. The French Selegiline Multicenter Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Selegiline as initial treatment in de novo parkinsonian patients

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Short-term beneficial effect of deprenyl monotherapy in early Parkinson's disease: a quantitative assessment

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Selegiline monotherapy in the treatment of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Symptomatic anti-parkinsonian effects of monoamine oxidase-B inhibition: comparison of selegiline and lazabemide

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Short review on monoamine oxidase and its inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Milacemide therapy for Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Effect of deprenyl on the progression of disability in early Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Selegiline: current perspectives on issues related to neuroprotection and mortality

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa. Parkinson Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

The effect of deprenyl and levodopa on the progression of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

The effects of early selegiline therapy on long-term levodopa treatment and parkinsonian disability: an interim analysis of a Norwegian--Danish 5-year study. Norwegian-Danish Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Selegiline as the primary treatment of Parkinson's disease--a long-term double-blind study.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

SELEDO: a 5-year long-term trial on the effect of selegiline in early Parkinsonian patients treated with levodopa

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Brain and brain monoamine oxidase in aging and in dementia of Alzheimer's type

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Expression of monoamine oxidase B activity in astrocytes of senile plaques.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Selegiline in treatment of behavioral and cognitive symptoms of Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Selegiline in the treatment of behavioural disturbance in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Treatment of Alzheimer's disease -- searching for a breakthrough, settling for less

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Milacemide: a placebo-controlled study in senile dementia of the Alzheimer type.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Maintenance on L-deprenyl prolongs life in aged male rats

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Chronic treatment of (-)deprenyl prolongs the life span of male Fischer 344 rats. Further evidence

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Sexually low performing male rats die earlier than their high performing peers and (-)deprenyl treatment eliminates this difference.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Long-term administration of (-)-deprenyl increases mortality in male Wistar rats

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a longterm study

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease. Parkinson Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Investigation by Parkinson's Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential i

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Causes of death need confirmation

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Parkinson's disease is rarely a primary cause of death

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Selegiline and mortality in Parkinson's disease: another view.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Mortality associated with selegiline in Parkinson's disease. What do the available data mean?

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Monitoring randomised controlled trials. Parkinson's disease trial illustrates the dangers of stopping early

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Selegiline, or the problem of early termination of clinical trials. The clinical questions are not well answered, and probably never will be.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Effect of selegiline on mortality in patients with Parkinson's disease: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Deprenyl, excess mortality, and epidemiological traps

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Antiparkinsonian agents. Drug interactions of clinical significance

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Lack of adverse interactions between concomitantly administered selegiline and citalopram

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2899%2900043-7

7 January 2021

10.1016/S1353-8020(99)00043-7

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18591148%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

1 reference